What do systematic reviews say?

Heparin vs pentasaccharide

It is very uncertain whether heparin changes adverse events (thrombocytopenia) compared with pentasaccharide (very low certainty).

• Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 8.25]
  1 study · 198 participants
  Very low

Heparin started before vs after the surgical procedure

The review found no eligible studies for this question.

• Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Higher‐dose heparin vs standard‐dose heparin

It is very uncertain whether higher‐dose heparin changes adverse events (thrombocytopenia) compared with standard‐dose heparin (very low certainty).

• Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
  RR 1.1 [0.07, 17.4]
  2 studies · 310 participants
  Very low

Bortezomib vs no bortezomib

Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).

• Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
  OR 2.05 [1.7, 2.48]
  8 studies · 3791 participants
  Low
• Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
  OR 1.51 [1.13, 2]
  3 studies · 1196 participants
  High
• Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
  OR 2.6 [2.01, 3.35]
  5 studies · 2595 participants
  Low

Cyclophosphamide vs mycophenolate

Cyclophosphamide showed no clear difference in adverse events: thrombocytopenia 12‐month compared with mycophenolate (low certainty).

• Cyclophosphamide for connective tissue disease–associated interstitial lung disease 2018 · Cochrane Headline outcomes only
  RD 0.03 [0, 0.06]
  2 studies · 300 participants
  Low

Heparin plus aspirin vs aspirin

• Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 140 participants
  GRADE not reported

Non‐platinum single‐agent vs non‐platinum combination treatment

It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  RR 1.58
  4 studies · 995 participants
  Very low

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found